Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Neurobiol Dis. 2019 Oct 17;134:104636. doi: 10.1016/j.nbd.2019.104636

Fig. 8.

Fig. 8.

Tg4510 mice vaccinated with tau vaccine AV-1980R/A display decreased levels of phospho tau in the posterior cortex soluble fraction when compared to AdvaxCpG adjuvant treated mice.

Phospho tau (pSer396), total tau (H150) and Nterm tau (Tau12) were assessed by western blot analysis (A, B, C representative WB images) in posterior cortex in RIPA soluble fraction.55 kda, 64 kda and combination of 55–64kda band intensity were quantified for H150 (D), pSer396 (E) and Tau12 (F) in Tg4510 mice treated with AdvaxCpG adjuvant or with AV-1980R. All groups were normalized to the adjuvant group and to actin. No bands were detected in non-transgenic (Ntg) and tet only (tTA) mice, as shown in image A, B, C. Ratio of Pser396 and Tau12 to H150 was calculated for bands 55–64 (G, H) and for bands 55 and 64 separately (Fig. S2). Data are presented as mean ± S.E.M., n = 12/group. Statistical significance was calculated against AdvaxCpG group using unpaired t-test *p < 0.05.